Compare Figs Inc (FIGS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Smith & Nephew plc — how do they compare? Figs Inc trades at $10.17 (market cap $1.66B), while Smith & Nephew plc trades at $31.28 (market cap $12.81B). The key difference: Smith & Nephew plc is far larger — about 7.7× Figs Inc's market cap, and Smith & Nephew plc pays a 2.54% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| FIGS | SNN | |
|---|---|---|
Market Cap | $1.66B | $12.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $38.70 |
52-Week Low | $5.81 | $28.73 |
Enterprise Value | $1.44B | $15.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $9.72, down 2.8% today, amid bearish technical signals despite recent earnings beats. Revenue grew to $631M in 2025 with a 66.6% gross margin, but net cash flow remains negative. Analyst consensus is bullish with a $19.50 price target, though technical indicators show selling pressure with RSI at neutral levels and ADX signaling a strong downtrend.
The stock presents a growth opportunity with strong fundamentals and analyst support, but faces near-term technical headwinds and margin pressures from tariffs and freight costs. Investors should weigh the 100% upside to consensus target against execution risks and persistent negative cash flow trends.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
